Advancing targeted cancer treatment – theranostics, tumour-sensing and drug delivery systems

What’s included?

Advancing precision with tumour-sensing technology

Surgery remains a primary treatment for cancer, particularly for solid tumours. Tumour-sensing technologies such as fluorescence-guided surgery, hyperspectral imaging and Raman spectroscopy are helping surgeons identify cancerous tissue with greater confidence, supporting more precise tumour removal while preserving healthy tissue.

As these technologies become integrated into minimally invasive and robot-assisted procedures, several technical challenges remain around signal specificity, miniaturisation and platform integration.

Download the white paper to explore the challenges and opportunities with tumour-sensing technology.

How radiotherapy and surgical ablation technologies are evolving

Radiotherapy has evolved over recent decades, with advancements in imaging and treatment delivery enabling clinicians to target tumours more accurately while limiting exposure to healthy tissue. Real-time imaging, adaptive treatment planning and targeted radiopharmaceuticals are helping to improve treatment precision and patient outcomes.

Approaches such as theranostics, adaptive radiotherapy, brachytherapy, histotripsy and irreversible electroporation are creating new possibilities for more personalised cancer treatment. However, translating these technologies into clinical practice presents challenges ranging from radiopharmaceutical production to compatibility with surgical instruments and integrating real-time treatment monitoring.

Download the white paper to find out how these approaches could support more precise and personalised cancer care.

Achieving targeted intratumoural drug delivery

Systemic drug therapies are a vital component of cancer care, however, they can be associated with toxicity and limited tumour penetration, often requiring higher volumes of expensive drugs. Delivering directly to tumours offers the potential to increase treatment effectiveness while reducing side effects, making intratumoural drug delivery a growing area of innovation.

Technologies such as pressure-enabled delivery systems, advanced needle designs and injectable hydrogels are being developed to overcome barriers including poor tumour penetration and uneven drug distribution. As targeted therapies, immunotherapies and cell therapies advance, delivering them directly into tumours will be essential to maximise their potential.

Download the white paper to discover new approaches in targeted drug delivery.

The future of targeted cancer treatment

Across surgical oncology, radiotherapy and drug delivery, medical device innovation offers:

• greater treatment precision
• more personalised therapies
• improved integration of imaging and treatment
• smarter real-time feedback systems
• less invasive interventions designed to improve patient outcomes.

For medical device developers, there are significant opportunities to accelerate the development of safer, smarter and more targeted treatments that support improved patient care.

Want to learn more?

Download the free white paper “Exploring the innovations in surgery, radiotherapy and drug delivery transforming cancer care” below for an in-depth look at the technologies shaping the future of oncology.